Latest News and Press Releases
Want to stay updated on the latest news?
-
Notice of election meeting for the holders of Equity Capital Certificates (ECCs) in SpareBank 1 SMN.
See attachments. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} 07:00 London, 09:00 Helsinki, 19 January 2012 -...
-
I forbindelse med Nykredit Portefølje Administration A/S´s overtagelse af administrationen af Investeringsforeningen Alm. Brand Invest offentliggøres herved ajourført prospekt for...
-
Chiffre d'affaires de Bourse Direct pour l'exercice 2011 : 33,6 millions d'euros, en hausse de 26,6% Plus de 29%1 de part de marché sur le secteur de la bourse en ligne Bourse Direct, acteur...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} BOUSSARD &...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} BOUSSARD &...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;}PÖYRY PLC Company Announcement 19 January 2012...
-
Phase III clinical study for filgrastim biosimilar (Neupogen®)[1] is expected to support expansion to the US marketPhase III study for Sandoz pegfilgrastim (Neulasta®) represents next major step in...
-
Phase III clinical study for filgrastim biosimilar (Neupogen®)[1] is expected to support expansion to the US marketPhase III study for Sandoz pegfilgrastim (Neulasta®) represents next major step in...
-
Below please find the 2012 financial calendar for The Scottish Salmon Company PLC 24.02.2012 Presentation Q4 2011 25.05.2012 Presentation Q1 2012 26.06.2012 Annual General Meeting 2012 ...